332 related articles for article (PubMed ID: 36874032)
1. Therapy resistance in neuroblastoma: Mechanisms and reversal strategies.
Zhou X; Wang X; Li N; Guo Y; Yang X; Lei Y
Front Pharmacol; 2023; 14():1114295. PubMed ID: 36874032
[TBL] [Abstract][Full Text] [Related]
2. Molecular targeting therapies for neuroblastoma: Progress and challenges.
Zafar A; Wang W; Liu G; Wang X; Xian W; McKeon F; Foster J; Zhou J; Zhang R
Med Res Rev; 2021 Mar; 41(2):961-1021. PubMed ID: 33155698
[TBL] [Abstract][Full Text] [Related]
3. Exosomes: Novel Players of Therapy Resistance in Neuroblastoma.
Richard H; Pokhrel A; Chava S; Pathania A; Katta SS; Challagundla KB
Adv Exp Med Biol; 2020; 1277():75-85. PubMed ID: 33119866
[TBL] [Abstract][Full Text] [Related]
4. RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma.
Singhal SS; Nagaprashantha L; Singhal P; Singhal S; Singhal J; Awasthi S; Horne D
Pharm Res; 2017 Aug; 34(8):1673-1682. PubMed ID: 28386633
[TBL] [Abstract][Full Text] [Related]
5. Neuroblastoma: Therapeutic strategies for a clinical enigma.
Modak S; Cheung NK
Cancer Treat Rev; 2010 Jun; 36(4):307-17. PubMed ID: 20227189
[TBL] [Abstract][Full Text] [Related]
6. Current management of neuroblastoma and future direction.
Pastor ER; Mousa SA
Crit Rev Oncol Hematol; 2019 Jun; 138():38-43. PubMed ID: 31092383
[TBL] [Abstract][Full Text] [Related]
7. The quest to develop an effective therapy for neuroblastoma.
Bhoopathi P; Mannangatti P; Emdad L; Das SK; Fisher PB
J Cell Physiol; 2021 Nov; 236(11):7775-7791. PubMed ID: 33834508
[TBL] [Abstract][Full Text] [Related]
8. ABC transporters and neuroblastoma.
Yu DM; Huynh T; Truong AM; Haber M; Norris MD
Adv Cancer Res; 2015; 125():139-70. PubMed ID: 25640269
[TBL] [Abstract][Full Text] [Related]
9. Dual-Targeting AKT2 and ERK in cancer stem-like cells in neuroblastoma.
Kim KW; Kim JY; Qiao J; Clark RA; Powers CM; Correa H; Chung DH
Oncotarget; 2019 Sep; 10(54):5645-5659. PubMed ID: 31608140
[TBL] [Abstract][Full Text] [Related]
10. Emerging therapeutic targets for neuroblastoma.
Aravindan N; Herman T; Aravindan S
Expert Opin Ther Targets; 2020 Sep; 24(9):899-914. PubMed ID: 33021426
[TBL] [Abstract][Full Text] [Related]
11. Advances in emerging drugs for the treatment of neuroblastoma.
Berlanga P; Cañete A; Castel V
Expert Opin Emerg Drugs; 2017 Mar; 22(1):63-75. PubMed ID: 28253830
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms and therapeutic targets in neuroblastoma.
Johnsen JI; Dyberg C; Fransson S; Wickström M
Pharmacol Res; 2018 May; 131():164-176. PubMed ID: 29466695
[TBL] [Abstract][Full Text] [Related]
13. Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions.
Zheng M; Kumar A; Sharma V; Behl T; Sehgal A; Wal P; Shinde NV; Kawaduji BS; Kapoor A; Anwer MK; Gulati M; Shen B; Singla RK; Bungau SG
Front Cell Dev Biol; 2024; 12():1353860. PubMed ID: 38601081
[TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma.
Alisi A; Cho WC; Locatelli F; Fruci D
Int J Mol Sci; 2013 Dec; 14(12):24706-25. PubMed ID: 24351843
[TBL] [Abstract][Full Text] [Related]
15. The Transcribed-Ultra Conserved Regions: Novel Non-Coding RNA Players in Neuroblastoma Progression.
Mudgapalli N; Shaw BP; Chava S; Challagundla KB
Noncoding RNA; 2019 Jun; 5(2):. PubMed ID: 31167408
[TBL] [Abstract][Full Text] [Related]
16. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
17. Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f.
Harvey H; Piskareva O; Creevey L; Alcock LC; Buckley PG; O'Sullivan MJ; Segura MF; Gallego S; Stallings RL; Bray IM
Int J Cancer; 2015 Apr; 136(7):1579-88. PubMed ID: 25137037
[TBL] [Abstract][Full Text] [Related]
18. Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus.
Mahller YY; Williams JP; Baird WH; Mitton B; Grossheim J; Saeki Y; Cancelas JA; Ratner N; Cripe TP
PLoS One; 2009; 4(1):e4235. PubMed ID: 19156211
[TBL] [Abstract][Full Text] [Related]
19. Targeting MYCN and ALK in resistant and relapsing neuroblastoma.
Tucker ER; Poon E; Chesler L
Cancer Drug Resist; 2019; 2(3):803-812. PubMed ID: 35582571
[TBL] [Abstract][Full Text] [Related]
20. Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers.
Prochazka P; Hrabeta J; Vicha A; Cipro S; Stejskalova E; Musil Z; Vodicka P; Eckschlager T
Oncol Rep; 2013 Jun; 29(6):2415-21. PubMed ID: 23563570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
